Skip to main content

Advertisement

SpringerLink
Log in

Treatment and Management of Dementia Due to Alzheimer’s Disease

  • Dementia (E McDade, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Alzheimer’s disease (AD) is a progressive neurological disorder typically associated with episodic memory loss as the initial symptom, but individuals <65 years old may present with executive dysfunction, word finding difficulties, or visual processing deficits. In those with AD, curative treatments are not available, but there are interventions which may modify disease course, symptom appearance and severity, enhance quality of life for patient and caregivers, and maintain safety. Both pharmacological and non-pharmacological interventions are important.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. McKhann GM et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s Dement. 2011;7(3):263–9.

    Article  Google Scholar 

  2. Odenheimer G et al. Quality improvement in neurology: dementia management quality measures. Neurology. 2013;81:1545–9. Brief overview of the dementia management quality measures with a link to the Physician Consortium for Performance Improvement Website.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Barnard ND et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35:S74–8.

    Article  PubMed  Google Scholar 

  4. Ngandu T et al. A 2 year multi-domain intervention of diet, exercise, cognitive training and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER); a randomized controlled trial. Lancet. 2015. doi:10.1016/S0140-6736(15)60461-5. Large, randomized controlled trial showing the importance of lifestyle modification in modifying cognitive decline.

    PubMed  Google Scholar 

  5. Singh B et al. Association of Mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;39(2):271–82.

    PubMed Central  PubMed  Google Scholar 

  6. van de Rest O et al. Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutri. 2015. doi:10.3945/an.114.007617.

    Google Scholar 

  7. Swaminathan A, Jicha GA. Nutrition and prevention of Alzheimer’s disease. Front Aging Neurosci. 2014. doi:10.3389/fnagi.2014.00282.

    PubMed Central  PubMed  Google Scholar 

  8. Ripjima A, Meulenbroek O, Olde Rikkert MGM. Cholinesterase inhibitors and add-on nutritional supplements in Alzheimer’s disease: a systematic review of randomized controlled trials. Ageing Res Rev. 2014;16:105–12.

    Article  Google Scholar 

  9. Forbes D et al. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2013;12, CD006489.

    PubMed  Google Scholar 

  10. Bossers WJ et al. A 9-week aerobic and strength training program improves cognitive and motor function in patients with dementia: a randomized, controlled trial. Am J Geriatr Psychiatry. 2015. doi:10.1016/j.jagp.2014.12.191.

    PubMed  Google Scholar 

  11. Brown D et al. Development of an exercise intervention to improve cognition in people with mild to moderate dementia: dementia and Physical Activity (DAPA) trial, registration ISRCTN32612072. Physiotherapy. 2015. doi:10.1016/j.physio.2015.01.002.

    PubMed  Google Scholar 

  12. Chokroverty S. Sleep and neurodegenerative diseases. Semin Neurol. 2009;29(4):446–67.

    Article  PubMed  Google Scholar 

  13. Kondratova AA et al. The circadian clock and pathology of the aging brain. Nat Rev Neurosci. 2012;13(5):325–35.

    CAS  PubMed Central  PubMed  Google Scholar 

  14. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev. 2014;3, CD009178.

    PubMed  Google Scholar 

  15. Xu J et al. Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2015. doi:10.1177/1533317514568005.

    Google Scholar 

  16. McCurry SM et al. Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer’s disease: results of a randomized, controlled trial. J Am Geriatr Soc. 2011;59:1393–402.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Molano J, Vaughn BV. Approach to insomnia in patients with dementia. Neurol Clin Pract. 2014;4(1):7–15.

    Article  Google Scholar 

  18. Ruthirakuhan M et al. Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and dementia: a review. J Aging Res. 2012. doi:10.3233/JAD-130866.

    PubMed Central  PubMed  Google Scholar 

  19. Hyde C et al. Evolution of the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model. Age and Aging. 2013;42:14–20.

    Article  Google Scholar 

  20. Tan CC et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615–31. doi:10.3233/JAD-132690.

    CAS  PubMed  Google Scholar 

  21. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1, CD005593.

    PubMed  Google Scholar 

  22. Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer’s disease. Curr Neuropharmacol. 2010;8(1):69–80.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Di Oliviera FF et al. Pharmacological modulation of cognitive and behavioral symptoms in patients with Alzheimer’s disease. J Neuro Sci. 2014;336(1–2):103–8.

    Article  Google Scholar 

  24. Kavanaugh S, VanBaelen B, Schӓuble B. Long term effects of galantamine on cognitive function in Alzheimer’s disease: a large scale international retrospective study. J Alzheimer’s Disord. 2011;27:521–30.

    Google Scholar 

  25. Lyle S et al. Treatment of whole population sample of Alzheimer’s disease with donepezil over a 4 year period: lessons learned. Dement Geriatr Cogn Disord. 2008;25:226–31.

    Article  CAS  PubMed  Google Scholar 

  26. Di Santo SG et al. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. J Alzheimers Dis. 2013;35(2):349–61. doi:10.3233/JAD-122140.

    PubMed  Google Scholar 

  27. Cummings JL et al. A practical algorithm for managing Alzheimer’s disease: what, when and why? Ann Clin Transl Neurol. 2015;2(3):307–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Massoud F, Desmarais JE, Gauthier S. Switching cholinesterase inhibitors in older adults with dementia. Int Psychogeriatri. 2011;23(3):372–8. Good review of studies that have investigated the switch of cholinesterase inhibitors in AD, with a practical approach in addressing intolerance and lack of efficacy with these medications.

    Article  Google Scholar 

  29. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from multidisciplinary expert panel. J Am Geriatr Soc. 2014;62:762–9.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Gitlin LN, Kales HC, Lyketsos CG. Managing behavioral symptoms in dementia using nonpharmacologic approaches: an overview. JAMA. 2012;308(19):2020–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Smits CH et al. Effects of combined intervention programs for people with dementia living at home and their caregivers: a systematic review. Int Geriatr Psychiatry. 2007;22(12):1181–93.

    Article  Google Scholar 

  32. Rosalynn Carter Institute for Caregiving. What Makes A Caregiver Program Effective? 2012. http://www.rosalynncarter.org/what_makes_caregiver_programs_effective/.

  33. Gitlin LN et al. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58(8):1465–74.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Kales HC and Gitlin LN. Assessment and management of behavioral and psychological symptoms of dementia. BMJ 2015;5:350:h369 doi:10.1136/bmjJ369. Excellent summary of NPS, factors contributing to symptoms, evidence for non-pharmacological and pharmacological interventions, theoretical framework and strategies for assessment, evaluations and management strategies for the clinician, initiating treatment plan and suggestions for collaboration and referral. Comprehensive reference list includes many historically and currently relevant articles on which knowledge is being built.

  35. Adelman RD et al. Care giver burden: a clinical review. JAMA. 2014;311(10):1052–9.

    Article  CAS  PubMed  Google Scholar 

  36. Cummings JL et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.

    Article  CAS  PubMed  Google Scholar 

  37. Steinberg M et al. Point and 5 year period prevalence of neuropsychiatric symptoms in dementia: the Cache county study. Int J Geriatr Psychiatry. 2008;23:170–7.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Thyrian JR et al. Burden of behavioral and psychiatric symptoms in people screened positive for dementia in primary care: results of the DelpHi Study. J Alzheimers Dis. 2015. doi:10.3233/JAD-143114.

    Google Scholar 

  39. Madhusoodanan S, Ting MB. Pharmacological management of behavior symptoms associated with dementia. World J Psychiatry. 2014;4(4):72–9.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Corbett A, Smith J, Creese B, Ballard C. Treatment of behavioral and psychological symptoms of Alzheimer’s disease. Curr Treat Options Neurol. 2012;14:113–25.

    Article  PubMed  Google Scholar 

  41. Tagariello P, Girardi P, Amore M. Depression and apathy in dementia: same syndrome or different constructs: a critical review. Arch Gerontol Geriatr. 2009;49(2):246–9.

    Article  CAS  PubMed  Google Scholar 

  42. Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatr. 2012;20(2):104–22.

    Article  Google Scholar 

  43. Rea R et al. Review article: apathy in Alzheimer’s disease: any effective treatment? Sci World J. 2014. doi:10.1155/2014/421385.

    Google Scholar 

  44. Enache D, Winblad B, Aarsland D. Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry. 2011;24(6):461–7.

    PubMed  Google Scholar 

  45. Ortega V et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2014;1, CD009125.

    Google Scholar 

  46. Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm. 2014;29(4):254–63.

    Article  PubMed  Google Scholar 

  47. Federal Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012. http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.

  48. Nassisi D et al. The evaluation and management of the acutely agitated patient. Mt Sinai J Med. 2006;73(7):976–84.

    PubMed  Google Scholar 

  49. Trihn NH et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer’s disease; a meta-analysis. JAMA. 2003;289(2):210–6.

    Article  Google Scholar 

  50. Seitz DP et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2, CD008819.

    Google Scholar 

  51. Pollock BG et al. A double blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatr. 2007;15:942–52.

    Article  Google Scholar 

  52. Porsteinsson AP et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Desai AK, Grossberg GT. Buspirone in Alzheimer’s disease. Expert Rev Neurother. 2003;3(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  54. Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;3, CD003945.

    PubMed  Google Scholar 

  55. Amann B et al. Anticonvulsants in the treatment of aggression in the demented elderly. Clin Pract Epidemiol Ment Health. 2009;5:14.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Seitz DP et al. Pharmacologic treatments for neuropsychiatric symptoms of dementia in long term care: a systematic review. Int Psychogenics. 2013;25(2):185–203.

    Article  Google Scholar 

  57. Wilcock GK et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of three studies. J Clin Psychiatry. 2008;69(3):341–8.

    Article  CAS  PubMed  Google Scholar 

  58. Schneider LS, Tariot PN, Dagerman KS, Davis SM. Effectiveness of atypical antipsychotics drugs in patients with Alzheimer’s disease. NEJM. 2006;355(15):1525–38.

    Article  CAS  PubMed  Google Scholar 

  59. Wang PS et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.

    Article  CAS  PubMed  Google Scholar 

  60. Maust DT et al. Antipsychotics, other psychotropics, and risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45.

    Article  PubMed  Google Scholar 

  61. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1, CD003476.

    PubMed  Google Scholar 

  62. Vigen CLP et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatr. 2011;168:831–9. Describes risk of worsening cognitive impairment with atypical antipsychotics.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Maher AR et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off label uses in adults: a systemic review and meta-analysis. J Am Med Assoc. 2011;306(12):1359–69.

    Article  CAS  Google Scholar 

  64. Corbett A, Burns A, Ballard C. Don’t use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ. 2014;349:g6420. doi:10.1136/bmj.g6420.

    Article  PubMed  Google Scholar 

  65. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo controlled trials. JAMA. 2005;294:1934–43. Study that initiated the FDA warning black box warning for atypical antipsychotics.

    Article  CAS  PubMed  Google Scholar 

  66. Ma H et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimer ’s Dis. 2014;42(3):915–37.

    Google Scholar 

  67. Ballard C et al. The dementia antipsychotic withdrawal trial (DART-AD): long term follow up of a randomized placebo-controlled trail. Lancet Neurol. 2009;8(2):151–7.

    Article  CAS  PubMed  Google Scholar 

  68. Declerq T. Withdrawal versus continuation of chronic antipsychotics drugs for behavioral and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2002; 3. CD007726.

  69. De Deyn PP et al. Aripiprazole in the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 2013;14(4):459–74.

    Article  PubMed  Google Scholar 

  70. Mintzer JE et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007;15(11):918–31.

    Article  PubMed  Google Scholar 

  71. Anand R et al. Therapeutics of Alzheimer’s disease: past, present, and future. Neuropharmacology. 2014;76:27–50.

    Article  CAS  PubMed  Google Scholar 

  72. Sperling RA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.

    Article  PubMed Central  PubMed  Google Scholar 

  73. Wang LY et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatr. 2009;17:744–51.

    Article  Google Scholar 

  74. Thurman DJ et al. Practice parameter: assessing patients in a neurology practice for risk of falls (an evidence-based review). Neurology. 2008;70:473–9.

    Article  PubMed  Google Scholar 

  75. Iverson DJ et al. Practice parameter update: evaluation and management of driving risk in dementia. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1316–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Arlt S et al. Adherence to medication in patients with dementia. Drugs Aging. 2008;25(12):1033–47.

    Article  PubMed  Google Scholar 

  77. Morris JC. The clinical dementia rating (CDR): current vision and scoring rules. Neurology. 1993;43:2412–4.

    Article  CAS  PubMed  Google Scholar 

  78. Chiachiaro J, Arnold RM, White DB. Reengineering advance care planning to create scalable, patient- and family-centered interventions. JAMA. 2015;313(11):1103–4.

    Article  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Jennifer Rose V. Molano, Robin Bratt, and Rhonna Shatz declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Neurology and Rehabilitation Medicine, The University of Cincinnati College of Medicine, 260 Stetson St., Suite 2300, P.O. Box 670525, Cincinnati, OH, 45267-0525, USA

    Jennifer Rose V. Molano MD, Robin Bratt RN, MSN, CNP & Rhonna Shatz DO

Authors
  1. Jennifer Rose V. Molano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin Bratt RN, MSN, CNP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rhonna Shatz DO
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Rose V. Molano MD.

Additional information

This article is part of the Topical Collection on Dementia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Molano, J.R.V., Bratt, R. & Shatz, R. Treatment and Management of Dementia Due to Alzheimer’s Disease. Curr Treat Options Neurol 17, 36 (2015). https://doi.org/10.1007/s11940-015-0363-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-015-0363-4

Keywords

Search

Navigation